| Quest Diagnostics Declares Quarterly Cash Dividend (PR Newswire) Quest Diagnostics Incorporated , the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on July 20, 2010, to shareholders of record of Quest Diagnostics common stock on July 6, 2010. us.rd.yahoo.com |
Arena Inks a Potential Blockbuster Deal KLLJ Investments submits: In my SA article from May, I discussed the potential value for Lorcaserin in the marketplace. As I stated then, " a partnership before approval can quickly change the game. I fully expect that to happen and once it does, we’ll have insight into how Big Pharma values a First Line Obesity Treatment."Complete Story » seekingalpha.com |
A Long Legacy of Affection The stress-reducing effects of affectionate mothering might last into children's mid-30s, according to a study in the Journal of Epidemiology and Community Health. online.wsj.com |
2 Year-End FDA Run-Up Stock Plays Mike Havrilla submits:Below are two small-cap stocks with expected FDA decisions by year-end and stock prices below $5 per share that I currently own as potential run-up plays with PDUFA action goal dates in late December for pending New Drug Applications (NDAs).On 8/30/10, Alimera Sciences (ALIM) was granted a priority (six-month) review for the ILUVIEN NDA that was filed 6/29/10 with expected FDA decision by 12/29/10, seeking approval for diabetic macular edema (DME). pSivida (PSDV) is due to receive $25M upon FDA approval + 20% profit sharing. In addition a MAA was filed for EU approval 7/8/10, and ALIM expects to complete the 3-year FAME study by year-end 2010 (this data not required for NDA), also expects to file a New Drug Submission (NDS) for Health Canada approval this month.Complete Story » seekingalpha.com |
Novartis Prices New M.S. Drug Novartis said its new drug for multiple sclerosis will have a wholesale price of about $48,000 a year per person in the U.S., making it among the most expensive drugs for the disease. online.wsj.com |